SanofiSNY stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent, a blockbuster drug Sanofi codeveloped with Regeneron ...

Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at week 24, ...